Phenotype and comparison groups
Define the most reliable functional phenotype and create comparison groups by response, model feature, dose or time.
R&D service
Mechanism & biomarker studies
Link tissue, functional and molecular results to treatment response and prioritize biomarker candidates for validation.
View imageAssay examples for mechanism studies
Tissue, molecular and functional assays for distinct study goals
HCC, kidney-injury and intestinal-barrier studies use histology, gene-expression analysis and tight-junction imaging to investigate model features and treatment response at tissue, molecular and functional levels.
Study focus
Questions we can help answer
- 01Which pathways change with the observed phenotype?
- 02Which biomarkers best distinguish response groups?
- 03Which results support the next study?
Study workflow
Connect reproducible phenotypes to mechanism and prioritize biomarker candidates
Connect baseline biology, treatment response and pathway changes. Confirm promising associations with additional samples and complementary methods.
Mechanism-focused readout panel
Select histology, imaging, flow, qPCR, protein or secreted readouts around the candidate pathway so every readout serves the scientific question.
Data integration and biomarker candidates
Compare baseline features, treatment response and mechanism readouts within model and batch context to identify reproducible response-associated candidates.
Independent validation of candidate markers
Confirm key findings in additional samples, with orthogonal methods or repeat perturbation, then assess candidate-marker reproducibility and its relevance to mechanism or response groups.
Study images and readouts
Tissue, molecular and functional assays across distinct studies
Explore tumor tissue, kidney injury and intestinal-barrier results. Combine relevant assays to investigate mechanisms and validate candidate biomarkers.
View imageCisplatin-associated molecular changes: RT-qPCR compares KIM-1, H2AFX and inflammation- and stress-related gene expression in H9-derived kidney organoids.
TRiCBIO H9-derived kidney organoid cisplatin studyView the kidney organoid injury study
View imageBarrier readout | FITC-positive area in matched fields: 0.023% control, 0.944% challenged. One representative field per group.
Study dataView the IBD model and barrier studyExpected study outputs
What you receive
Phenotype and molecular data
Functional, morphological, histological and molecular results from the agreed assays, with model and batch information.
Mechanistic insights & candidate markers
Integrate supporting findings, identify associations for follow-up testing and explain how candidate markers were selected.
Follow-up priorities and plan
Prioritized findings, orthogonal confirmation methods and additional sample requirements for the next study.
Relevant model systems
Relevant model systems
TRiCBIO studies in IBD barrier biology, kidney injury, tumor apoptosis and tumor immunity combine morphological, functional and molecular readouts. Candidate signals can then be advanced through additional samples, orthogonal methods and prespecified analyses to support mechanism and follow-on biomarker research.
PROJECT DISCUSSION
Test the mechanism behind the observed phenotype
Share the observed phenotype, comparison groups, available data and mechanism hypothesis. Our scientists will select molecular, functional and orthogonal assays to test that hypothesis.